Abstract Details

Title The Comorbidity Burden in Patients with Cluster Headache

Topic Headache

Presentation(s) P01 - (-)

Poster/Presentation
Number 083

Objective

Background Few large, high quality studies have examined the comorbidity burden of patients with cluster headache (CH). A recent web-based survey identified a high prevalence of suicidal ideation in this population, suggesting a high psychiatric burden. The population surveyed, however, was not representative of CH sufferers in general, and compared respondents with the US population rather than age and sex-matched controls.

Design/Methods We used the Partners Research Patient Data Registry (RPDR) to identify unique patients diagnosed with cluster headache 2002-2012 and conducted a population based study. The RPDR is a relational database containing clinical and administrative information on millions of patients. Within this group, we searched for selected comorbidities. We plan to obtain approval to contact patients to confirm their clinical course and comorbidities.

Results We identified 170 ± 3 unique patients diagnosed with cluster headache 2002-2012. 51% had used antidepressants; 20% had been diagnosed with anxiety disorders; 25% with depression, 23% with hypertension, 21% with hyperlipidemia, 7.6% with diabetes mellitus, 7% with ischemic heart disease, 6% with obesity, 4% with organic sleep disorders, 13% with cardiovascular disease, 10.5% with trigeminal neuralgia and 4.7% with epilepsy.

Conclusions Our findings provide high quality information on the prevalence of comorbidities in a complete sample of all patients with CH seen in a large academic medical system over the course of a decade. They suggest that the burden of comorbidities in cluster headache is high. The comorbidity burden of CH may provide clues to the pathophysiology and clinical course of CH. From a research perspective, information about common comorbidities might point to shared biologic mechanisms that could be exploited for treatment purposes.

Authors/Disclosures
Shivang Joshi, MD (Community Neuroscience Services) PRESENTER	Dr. Joshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Joshi has received personal compensation in the range of $0-$499 for serving as a Consultant for Nerivio. Dr. Joshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Joshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Joshi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Joshi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for lundbeck. Dr. Joshi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for scilex. The institution of Dr. Joshi has received research support from Biohaven.
Jiwon Oh, MD, FAAN (St Michael's Hospital)	Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from Roche.
Elizabeth Loder, MD, MPH	Dr. Loder has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. The institution of Dr. Loder has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The BMJ.

��ɫ��

��ɫ��